Results 181 to 190 of about 6,102 (207)

Individualization of Treatments with Drugs Metabolized by CES1: Combining Genetics and Metabolomics

Pharmacogenomics, 2015
CES1 is involved in the hydrolysis of ester group-containing xenobiotic and endobiotic compounds including several essential and commonly used drugs. The individual variation in the efficacy and tolerability of many drugs metabolized by CES1 is considerable. Hence, there is a large interest in individualizing the treatment with these drugs. The present
Rasmussen, H.B., Bjerre, D., Linnet, K., Juergens, G., Dalhoff, K., Stefansson, H., Hankemeier, T., Kaddurah-Daouk, R., Taboureau, O., Brunak, S., Houmann, T., Jeppesen, P., Pagsberg, A.K., Plessen, K., Dyrborg, J., Hansen, P.R., Hansen, P.E., Hughes, T., Werge, T.   +18 more
openaire   +4 more sources

Reappraisal of the Genetic Diversity and Pharmacogenetic Assessment of CES1

Pharmacogenomics, 2017
The CES1 gene encodes a hydrolase that metabolizes important drugs. Variants generated by exchange of segments with CES1P1 complicate genotyping of CES1. Using a highly specific procedure we examined DNA samples from 200 Caucasians and identified 46 single nucleotide variants (SNVs) in CES1 and 21 SNVs in CES1A2, a hybrid composed of CES1 and CES1P1 ...
Laura Ferrero-Miliani, Ditte Bjerre, Claus Stage, Majbritt Busk Madsen, Gesche Jűrgens, Kim Peder Dalhoff, null INDICES, Henrik Berg Rasmussen   +7 more
openaire   +3 more sources

Pharmacogenetic study of CES1 gene and enalapril efficacy

Journal of Applied Genetics
Enalapril is an orally administered angiotensin-converting enzyme inhibitor which is widely prescribed to treat hypertension, chronic kidney disease, and heart failure. It is an ester prodrug that needs to be activated by carboxylesterase 1 (CES1). CES1 is a hepatic hydrolase that in vivo biotransforms enalapril to its active form enalaprilat in order ...
Misbah Hussain, Sehrish Basheer, Adila Khalil, Qurat Ul Ain Haider, Hafsa Saeed, Muhammad Faizan   +5 more
openaire   +2 more sources

Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung

Biochemical Pharmacology, 2018
Lungs are pharmacologically active organs and the pulmonary drug metabolism is of interest for inhaled drugs design. Carboxylesterases (CESs) are enzymes catalyzing the hydrolysis of many structurally different ester, amide and carbamate chemicals, including prodrugs.
Gabriele Morena, Puccini Paola, Lucchi Marco, Vizziello Anna, Gervasi Pier Giovanni, Longo Vincenzo   +5 more
openaire   +4 more sources

Carboxylesterase 1 (Ces1): from monocyte marker to major player

Journal of Clinical Pathology, 2010
There are few, if any, enzymes that have been studied by, and have importance in, so many and varied disciplines as has monocyte esterase/Ces 1. In this review its involvement in the fields of histochemistry, haematology, toxicology, pharmacology, therapeutics, and tumour cell killing, immune surveillance and malignant disease, is briefly described.
openaire   +2 more sources

Carboxylesterase 1 (Ces1) Releases Oxylipins From Oxidized Triacylglycerols: Examination of Its Substrate Selectivity

The FASEB Journal, 2022
Triacylglycerols (TAGs) are the most quantitatively important storage form of fat and are found primarily in cytoplasmic lipid droplets within cells. TAGs are broken down to its component free fatty acids by lipolytic enzymes when fuel reserves are required. However, when TAGs possess large quantities of polyunsaturated fatty acids
Matthew K. Ross, Maggie Phillips, Abdolsamad Borazjani   +2 more
openaire   +1 more source

Pyrazolone compounds could inhibit CES1 and ameliorates fat accumulation during adipocyte differentiation

Bioorganic Chemistry
Carboxylesterase 1 (CES1), a member of the serine hydrolase superfamily, is involved in a wide range of xenobiotic and endogenous substances metabolic reactions in mammals. The inhibition of CES1 could not only alter the metabolism and disposition of related drugs, but also be benefit for treatment of metabolic disorders, such as obesity and fatty ...
Dan-Dan Wang, Zhen-Zhen Wang, Wen-Cai Liu, Xing-Kai Qian, Ya-Di Zhu, Tie-Gang Wang, Shu-Mei Pan, Li-Wei Zou   +7 more
openaire   +2 more sources

Abstract 3620: Tumor targeted delivery of glutamine antagonist: Use of CES1-/- mice

Cancer Research, 2019
Abstract 6-diazo-5-oxo-L-norleucine (DON), a potent glutamine antagonist, broadly blocks glutamine utilizing reactions critical for the synthesis of nucleic acids, amino acids, proteins and the generation of alpha-ketoglutarate for energy metabolism.
Rana Rais, Jesse Alt, Ranjeet Dash, Lukáš Tenora, Pavel Majer, Barbara S. Slusher   +5 more
openaire   +1 more source

The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans

European Journal of Clinical Pharmacology, 2012
The aim of this study was to examine whether carboxylesterase 1 (CES1A) genetic polymorphisms affect the pharmacokinetics of oseltamivir.Thirty healthy Japanese male and female subjects ranging in age from 20 to 36 years voluntarily participated in this study.
Yuki, Suzaki, Naoto, Uemura, Makoto, Takada, Tetsuji, Ohyama, Akiko, Itohda, Takuya, Morimoto, Hiromitsu, Imai, Hajime, Hamasaki, Akihiro, Inano, Masakiyo, Hosokawa, Masato, Tateishi, Kyoichi, Ohashi   +11 more
openaire   +2 more sources

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect

Drug Metabolism and Drug Interactions, 2014
Abstract Human carboxylesterase 1 (CES1) and carboxylesterase 2 (CES2) are serine esterases responsible for the hydrolysis of ester and amide bonds present in a number of pharmaceutical products. Several common genetic variants of the CES1 and CES2 genes have been shown to influence drug metabolism and clinical outcomes. Polymorphisms of
Zahra, Merali, Stephanie, Ross, Guillaume, Paré   +2 more
openaire   +2 more sources